ESMO26: Other skin cancer advances beyond groundbreaking cancer vaccine
Regeneron presented Phase III data for Libtayo (cemiplimab) in skin cancer, showing a 37% reduction in death risk. Pfizer's STARBOARD trial showed Keytruda triplet therapy improved outcomes in melanoma. Both studies were discussed at ESMO 2026.
How this was made
The 30-second read
Why it matters
These first‑report trial results are likely to move the stocks of the involved companies as investors reassess growth prospects in oncology.
Market read
First‑time disclosure of pivotal oncology trial data; high relevance for biotech equities and sector sentiment.
What to watch
Potential safety concerns and cost of combination therapies could temper enthusiasm.
Background
The article summarizes newly released Phase III data from three major pharma companies presented at ESMO 2026, each showing significant efficacy improvements in melanoma or cutaneous squamous cell carcinoma.
Ticker impact
Moderna co‑developed the melanoma vaccine with Merck, delivering the same 42% risk reduction.
potential upside as investors value the vaccine partnership.
New efficacy data directly ties to Moderna's oncology pipeline.
Regeneron's Libtayo showed a 37% reduction in death risk in high‑risk CSCC patients in the C‑POST trial.
likely upward pressure from improved OS outlook.
First report of long‑term survival benefit with crossover accounted for.
Pfizer's STARBOARD trial reported a 70% ORR and 67% PFS reduction with a Keytruda‑Braftovi‑Mektovi triplet in melanoma.
likely upward pressure as market digests the triplet efficacy.
First disclosure of a high‑impact melanoma combination trial.
Market effects
Boosts broader oncology and immunotherapy sector sentiment.
Positive for US biotech and pharma stocks.
Highlights progress in melanoma treatments worldwide.
Counterpoint
Skeptics may question durability of benefit given high crossover rates.
Key entities
- CompanyMerck & Co.
Co‑developer of the melanoma vaccine with Moderna.
- CompanyModerna
Partner in the melanoma vaccine trial.
- CompanyRegeneron Pharmaceuticals
Manufacturer of Libtayo (cemiplimab) for CSCC.
- CompanyPfizer
Developer of the STARBOARD melanoma triplet regimen.
